- Market Capitalization, $K 2,866,901
- Shares Outstanding, K 157,522
- Annual Sales, $ 1,094 M
- Annual Income, $ -139,310 K
- 60-Month Beta 1.76
- Price/Sales 2.65
- Price/Cash Flow 30.03
- Price/Book 2.74
|Period||Period Low||Period High||Performance|
| || |
-3.82 (-17.95%)since 12/24/19
| || |
-2.01 (-10.33%)since 10/24/19
| || |
-15.60 (-47.14%)since 01/24/19
Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $17.38 to a high of $18.46. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $18.12...
In the latest trading session, Alkermes (ALKS) closed at $19.99, marking a -0.05% move from the previous day.
Alkermes (ALKS) closed the most recent trading day at $19.52, moving +1.61% from the previous trading session.
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00...
LGND vs. ALKS: Which Stock Is the Better Value Option?
Shares of Alnylam (ALNY) rise on significant pipeline progress.
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
New Strong Buy Stocks for December 26th
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $21.12 to a high of $21.56. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $21.29...